Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 8/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366853 | 1.00 | P2RY14 (0.55) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL552611 | 0.90 | SLC28A1 (0.60) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL28714767 | 0.86 | P2RY14 (0.59) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL17728069 | 0.85 | P2RY14 (0.61) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL6754596 | 0.84 | P2RY14 (0.61) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL17065224 | 0.83 | P2RY14 (0.54) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL7611038 | 0.82 | P2RY14 (0.61) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL5964450 | 0.82 | P2RY14 (0.61) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL19462556 | 0.80 | P2RY2 (0.47) | P2RY14P2RY2P2RY6P2RY4SLC28A1 | |
| SCHEMBL6028058 | 0.80 | P2RY14 (0.69) | P2RY14P2RY2P2RY6P2RY4SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748382-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748381-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260109983-A1 | HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWAL | BAYLOR COLLEGE OF MEDICINE (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3826720-B1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | SILENCE THERAPEUTICS GMBH (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4717773-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | Silence Therapeutics GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-3710585-B1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | SILENCE THERAPEUTICS GMBH (DE) | 2026-02-25 | — | — | EP | disclosed |
| EP-4674963-A2 | HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWAL | Baylor College of Medicine (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12497466-B2 | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities | ATYR PHARMA, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12480120-B2 | Hippo and dystrophin complex signaling in cardiomyocyte renewal | BAYLOR COLLEGE OF MEDICINE (US) | 2025-11-25 | — | — | US | disclosed |
| US-20020177568-A1 | Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B | RIBOZYME PHARMACEUTICALS, INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002094185-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| EP-1257639-A2 | NUCLEOZYMES WITH ENDONUCLEASE ACTIVITY | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001059103-A9 | METHOD AND REAGENT FOR THE MODULATION AND DIAGNOSIS OF CD20 AND NOGO GENE EXPRESSION | RIBOZYME PHARM INC (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020142980-A1 | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression | RIBOZYME PHARMACEUTICALS INC. | 2002-10-03 | — | — | US | disclosed |
| US-20020102568-A1 | Nucleic acid sensor molecules | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001066721-A2 | NUCLEIC ACID SENSOR MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001059102-A2 | NUCLEOZYMES WITH ENDONUCLEASE ACTIVITY | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001059103-A2 | METHOD AND REAGENT FOR THE MODULATION AND DIAGNOSIS OF CD20 AND NOGO GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001057206-A2 | METHOD AND REAGENT FOR THE INHIBITION OF CHECKPOINT KINASE-1 (CHK 1) ENZYME | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109983-A1 | HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWAL | ACTN1, TNNC1, MYLK2 | P2RY14 4199/4885P2RY2 4052/4885P2RY6 4279/4885 |
| US-20020102568-A1 | Nucleic acid sensor molecules | ZFR, GDA, ADAR | P2RY14 1667/4885P2RY2 3137/4885P2RY6 2355/4885 |
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | LPAR2, LPCAT1, LPAR1 | P2RY14 620/4885P2RY2 442/4885P2RY6 1484/4885 |
| US-20020142980-A1 | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression | NSUN2, RNMT, NSUN3 | P2RY14 4652/4885P2RY2 4402/4885P2RY6 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.